Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

pharmafile | April 14, 2020 | News story | Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb 

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s patents.

In December, a California jury decided to award Bristol-Myers Squibb $752 million regarding Gilead’s CAR-T treatment Yescarta. Gilead had acquired Kite Pharma in 2017 to gain Yescarta, and Bristol-Myers Squibb alleged the treatment’s development was based on a patent owned by Juno therapeutics, that BMS acquired in 2018.

As a result of the new ruling, US District Judge Philip S. Gutierrez boosted the amount Gilead owes BMS from $752 million to $1.2 billion. This additional cost is labelled as “enhanced damages.”

Gilead plans to appeal the verdict and told the Times it believes that the ruling is legally “unsupportable” and the company believes it will be reversed. They maintain that Kite developed Yescarta independently and did not infringe on the Juno’s patent.

Yescarta was first approved by the FDA in 2017, and was the first CAR-T treatment for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

Conor Kavanagh

Related Content

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech …


‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge …

Bristol Myers Squibb building in New Jersey

Bristol Myers Squibb psoriasis drug shows positive Phase III results

Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown …

Latest content